View Archive »
About The Cover
GRP-R and FAK expressions correlate to neuroblastoma malignancy and GRP-induced FAK activation. More intense immunofluorescence of FAK and GRP-R were observed in BE(2)-C cells when compared to SK-N-SH cells. The figure of BE(2)-C was digitally enhanced for the cover of Oncotarget. See Lee et al.
|
|
Table of Contents
Editorial
|
| The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer |
|
https://doi.org/10.18632/oncotarget.771
|
| 1483-1484 |
|
| PI3Kβ downstream of GPCRs – crucial partners in oncogenesis |
|
https://doi.org/10.18632/oncotarget.787
|
| 1485-1486 |
|
| Endotrophin – Linking Obesity with Aggressive Tumor Growth |
|
https://doi.org/10.18632/oncotarget.796
|
| 1487-1488 |
|
| Attacking MALT1 for ABCDLBCL therapy |
|
https://doi.org/10.18632/oncotarget.794
|
| 1489-1490 |
|
| mTOR inhibitor efficacy is determined by the eIF4E/4EBP ratio |
|
https://doi.org/10.18632/oncotarget.799
|
| 1491-1492 |
|
| Targeting Lymphomas Through MALT1 Inhibition |
|
https://doi.org/10.18632/oncotarget.819
|
| 1493-1494 |
|
| PU1 is a tumor suppressor for B cell malignancies |
|
https://doi.org/10.18632/oncotarget.800
|
| 1495-1496 |
|
| Tumorinfiltrating macrophages cancer stem cells and therapeutic responses |
|
https://doi.org/10.18632/oncotarget.792
|
| 1497-1498 |
|
| Coordinate PI3K pathway and Bcl2 family disruption in AML |
|
https://doi.org/10.18632/oncotarget.809
|
| 1499-1500 |
|
| Targeting Tumor Stroma: Exploiting Apoptotic Priming |
|
https://doi.org/10.18632/oncotarget.830
|
| 1501-1502 |
|
| The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome |
|
https://doi.org/10.18632/oncotarget.780
|
| 1503-1504 |
Reviews
|
| Advances in Targeting Signal Transduction Pathways |
|
https://doi.org/10.18632/oncotarget.802
|
| 1505-1521 |
|
| Recent progress in genetics of aging senescence and longevity: focusing on cancerrelated genes |
|
https://doi.org/10.18632/oncotarget.889
|
| 1522-1532 |
Research Papers
|
| Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 |
|
https://doi.org/10.18632/oncotarget.747
|
| 1533-1545 |
|
| Downregulation of Sox7 is associated with aberrant activation of Wnt/βcatenin signaling in endometrial cancer |
|
https://doi.org/10.18632/oncotarget.667
|
| 1546-1556 |
|
| All tyrosine kinase inhibitorresistant chronic myelogenous cells are highly sensitive to Ponatinib |
|
https://doi.org/10.18632/oncotarget.692
|
| 1557-1565 |
|
| PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes |
|
https://doi.org/10.18632/oncotarget.716
|
| 1566-1575 |
|
| FAK is a critical regulator of neuroblastoma liver metastasis |
|
https://doi.org/10.18632/oncotarget.732
|
| 1576-1587 |
|
| Smallmolecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem and progenitor cells in acute myeloid leukemia AML |
|
https://doi.org/10.18632/oncotarget.733
|
| 1588-1599 |
|
| Autophagyrelated gene 12 ATG12 is a novel determinant of primary resistance to HER2targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment |
|
https://doi.org/10.18632/oncotarget.742
|
| 1600-1614 |
|
| A combination of temsirolimus an allosteric mTOR inhibitor with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.762
|
| 1615-1628 |
|
| Development of an orallyadministrative MELKtargeting inhibitor that suppresses the growth of various types of human cancer |
|
https://doi.org/10.18632/oncotarget.790
|
| 1629-1640 |
|
| Lin28b Promotes Head and Neck Cancer Progression via Modulation of the InsulinLike Growth Factor Survival Pathway |
|
https://doi.org/10.18632/oncotarget.785
|
| 1641-1652 |
|
| Stress Response of Glioblastoma Cells Mediated by miR175p Targeting PTEN and the Passenger Strand miR173p Targeting MDM2 |
|
https://doi.org/10.18632/oncotarget.810
|
| 1653-1668 |
|
| STAT5 triggers BCRABL1 mutation by mediating ROS production in chronic myeloid leukaemia |
|
https://doi.org/10.18632/oncotarget.806
|
| 1669-1687 |
|
| Simalikalactone E SkE a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway |
|
https://doi.org/10.18632/oncotarget.791
|
| 1688-1699 |
|
| Gene expressionbased risk score in diffuse large Bcell lymphoma |
|
https://doi.org/10.18632/oncotarget.807
|
| 1700-1710 |
Research Perspectives
|
| Common drugs and treatments for cancer and agerelated diseases: revitalizing answers to NCI’s provocative questions |
|
https://doi.org/10.18632/oncotarget.890
|
| 1711-1724 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
